Insiders who reported open-market trades in the last 12 months at the companies Charles N. York II files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jeremy Bender - $321K in DAWN purchases and sales in the last 12 months
Adam Dubow - $113K in DAWN purchases and sales in the last 12 months
Lauren Merendino - $101K in DAWN purchases and sales in the last 12 months
Charles N. York II is a corporate insider, tracked as COO and CFO of Day One Biopharmaceuticals, Inc. (DAWN). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Charles N. York II last file a Form 4?
The most recent primary Form 4 on record is dated 23 April 2026, one of 7 filings going back to 2024.
Has Charles N. York II been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($169K) across all tracked filings.
Charles N. York II is COO and CFO of Day One Biopharmaceuticals, Inc. (DAWN). 7 SEC Form 4 filings on record going back to 2024, most recently on 23 April 2026. Most recent open-market trade: sold $70K of DAWN on 18 February 2026. Lifetime open-market sales: $169K.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Charles N. York II.
InsiderAlpha's records for Charles N. York II go back to 2024: 7 primary Form 4 filings, an average of 2.3 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
